The Peter Attia Drive

<p><a href= "https://peterattiamd.com/tomdayspring8/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260608-pod-tomdayspring8&utm_content=260608-pod-tomdayspring8-podfeed"> View the Show Notes Page for This Episode</a></p> <p><a href= "https://peterattiamd.com/subscribe/?utm_source=podcast-feed&tomdayspring8%20=referral&utm_campaign=260126-pod-lisamosconi&utm_content=260608-pod-tomdayspring8-podfeed"> Become a Member to Receive Exclusive Content</a></p> <p><a href= "https://peterattiamd.com/newsletter/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260608-pod-tomdayspring8&utm_content=260608-pod-tomdayspring8-podfeed"> Sign Up to Receive Peter's Weekly Newsletter</a></p> <p>Tom Dayspring is a world-renowned lipidologist and one of the most thoughtful teachers in the field of lipid metabolism. In this episode, Tom returns to The Drive for a deep dive into the relationship between lipids and brain health, beginning with the fundamentals of cholesterol transport before exploring why the brain's cholesterol system operates almost entirely independently from the rest of the body. Tom examines the roles of apoB, apoA-I, and especially apoE in cholesterol homeostasis, discusses how APOE genotype influences Alzheimer's disease risk, and unpacks the complex links between cholesterol metabolism, amyloid, and tau pathology. He also reviews what is currently known—and still uncertain—about the effects of statins, ezetimibe, omega-3 fatty acids, and emerging CETP inhibitors on brain health and neurodegenerative disease risk. Although highly technical, this conversation provides an essential framework for understanding the nuanced relationship between lipid-lowering therapies, cardiovascular disease prevention, and neurodegenerative diseases in an area often clouded by misinformation.</p> <p><strong>We discuss:</strong></p> <ul type="disc"> <li>The fundamentals of cholesterol transport in the body, and how peripheral cholesterol metabolism differs from cholesterol handling in the brain [2:45];</li> <li>How cholesterol is transported through plasma and stored within cells, and why lowering LDL cholesterol does not deplete the body or brain of cholesterol [11:45];</li> <li>How apoB particles drive atherosclerosis, why lowering lipids matters, and the factors that influence individual cardiovascular risk [20:00];</li> <li>How the brain produces and transports its own cholesterol using apoE lipoproteins independently of circulating cholesterol and apoB-containing lipoproteins [29:00];</li> <li>How apoB structure influences LDL receptor binding and LDL clearance [39:00];</li> <li>How neurons acquire cholesterol from apoE-containing lipoproteins and why desmosterol serves as a unique marker of cholesterol synthesis in the brain [41:45];</li> <li>The difference between the APOE gene and the apoE protein, the major APOE genotypes found in humans, and how APOE4 influences Alzheimer's disease risk [48:45];</li> <li>HDL function beyond cholesterol: immune function, protein cargo, and communication with the brain [53:30];</li> <li>How APOE4-associated defects in brain cholesterol transport may promote Alzheimer's disease: amyloid production, neuronal cholesterol homeostasis, and cholesterol clearance [58:00];</li> <li>Statins and brain health: reviewing the evidence of the potential impact of statins on cognition and Alzheimer's disease risk [1:09:00];</li> <li>Desmosterol and 24S-hydroxycholesterol as biomarkers of brain cholesterol metabolism and statin effects [1:17:15];</li> <li>Possible cognitive benefits of ezetimibe beyond lowering apoB [1:19:30];</li> <li>EPA, DHA, and the evidence for omega-3 fatty acids in brain health [1:23:15];</li> <li>Obicetrapib: an emerging CETP inhibitor with potential implications for both cardiovascular and brain health [1:31:00]; and</li> <li>More.</li> </ul> <p>Connect With Peter on <a href= "https://twitter.com/PeterAttiaMD">Twitter</a>, <a href= "https://www.instagram.com/peterattiamd/">Instagram</a>, <a href="https://www.facebook.com/peterattiamd/">Facebook</a> and <a href="https://www.youtube.com/channel/UC8kGsMa0LygSX9nkBcBH1Sg">YouTube</a></p>

<p><a href= "https://peterattiamd.com/sleeppharmacology/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260601-pod-sleeppharmacology&utm_content=260601-pod-genetictesting-podfeed"> View the Show Notes Page for This Episode</a></p> <p><a href= "https://peterattiamd.com/subscribe/?utm_source=podcast-feed&sleeppharmacology=referral&utm_campaign=260601-pod-sleeppharmacology&utm_content=260601-pod-sleeppharmacology-podfeed"> Become a Member to Receive Exclusive Content</a></p> <p><a href= "https://peterattiamd.com/newsletter/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260601-pod-sleeppharmacology&utm_content=260601-pod-sleeppharmacology-podfeed"> Sign Up to Receive Peter's Weekly Newsletter</a></p> <p>In this episode, Peter dives into the pharmacology of sleep, exploring where sleep medications fit within the broader framework of achieving healthy, restorative sleep. He explains why sleep is a biological imperative, why behavioral and environmental interventions must remain the foundation of good sleep, and how medications can serve as useful tools when carefully matched to a person's specific sleep problem. Peter examines the major classes of prescription sleep medications, including how they work, their effects on sleep architecture, their duration of action, side effects, and risks of tolerance and dependence. He also discusses the dangers of using sleep drugs without a clear understanding of the underlying problem being treated, the role of medications as short-term bridges during periods of acute stress, pain, or anxiety, and the promise that newer drugs like DORAs may hold for Alzheimer's prevention in high-risk individuals. Finally, Peter reviews the evidence for select off-label medications and supplements commonly used for sleep.</p> <p><strong>We discuss:</strong></p> <ul type="disc"> <li>The biological foundations of sleep, the major drivers of sleep dysfunction, and the role sleep medications can play when appropriately matched to specific sleep problems [1:00];</li> <li>Sleep hygiene, circadian alignment, and the medical causes of insomnia: building the foundation for effective sleep treatment [7:15];</li> <li>Understanding insomnia: hyperarousal, CBT-I, paradoxical insomnia, and why different sleep problems require different treatments [12:45];</li> <li>The difference between sedation and physiologic sleep: sleep architecture, restorative sleep stages, and matching medications to specific sleep problems [17:00];</li> <li>Benzodiazepines for insomnia: mechanisms, effects on sleep architecture, and the risks of long-term use [18:45];</li> <li>Z-drugs for insomnia: how Ambien, Sonata, and Lunesta work, and the ongoing risks of sleep medications targeting GABA systems [23:00];</li> <li>Dual orexin receptor antagonists (DORAs) and the future of sleep medicine: orexin signaling, sleep architecture, and the emerging connection between sleep and Alzheimer's disease [27:15];</li> <li>Melatonin for circadian timing: how timing signals differ from sedatives in the treatment of sleep disorders [36:30];</li> <li>Trazodone for insomnia: preserving deep sleep while minimizing the risks of traditional sedative-hypnotics [42:00];</li> <li>First-generation antihistamines for sleep: short-term sedation, anticholinergic risks, and concerns about long-term cognitive health [44:00];</li> <li>Sleep supplements and the evidence behind them: glycine, magnesium, ashwagandha, phosphatidylserine, and more [45:45];</li> <li>Takeaways: supplement quality, individualized sleep treatment, and the importance of matching interventions to the biology of insomnia [52:00]; and</li> <li>More.</li> </ul> <p>Connect With Peter on <a href= "https://twitter.com/PeterAttiaMD">Twitter</a>, <a href= "https://www.instagram.com/peterattiamd/">Instagram</a>, <a href="https://www.facebook.com/peterattiamd/">Facebook</a> and <a href="https://www.youtube.com/channel/UC8kGsMa0LygSX9nkBcBH1Sg">YouTube</a></p>

<p><a href= "https://peterattiamd.com/ama85/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260518-pod-ama85&utm_content=260518-pod-ama85-podfeed"> View the Show Notes Page for This Episode</a></p> <p><a href= "https://peterattiamd.com/subscribe/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260518-pod-ama85&utm_content=260518-pod-ama85-podfeed"> Become a Member to Receive Exclusive Content</a></p> <p><a href= "https://peterattiamd.com/newsletter/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260518-pod-ama85&utm_content=260518-pod-ama85-podfeed"> Sign Up to Receive Peter's Weekly Newsletter</a></p> <p>In this "Ask Me Anything" (AMA) episode, Peter explores how to think critically about medications and supplements by focusing not on whether an intervention is inherently "good" or "bad," but on whether it makes sense for a specific person with a specific problem. He explains why clearly defining the problem matters more than choosing the intervention itself, how the intended purpose of a medication or supplement should influence the standard of evidence required, and why mechanistic reasoning alone is rarely enough to justify taking something. Peter also examines how baseline risk shapes the true benefit of an intervention, why relative risk statistics can be misleading without proper context, and how to weigh not only side effects, but also cost, inconvenience, and opportunity cost when deciding whether something is worth taking. Additionally, he discusses practical ways to evaluate whether a supplement is actually having a meaningful effect, how to think about discontinuing therapies, why supplements deserve far more skepticism than they often receive, and the small group of over-the-counter supplements he believes may offer a reasonable risk-reward trade-off.</p> <p>If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your <a href= "https://peterattiamd.com/members/private-podcast-feed/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260518-pod-ama85&utm_content=260518-pod-ama85-podfeed">private RSS feed </a>or our website at the <a href= "http://peterattiamd.com/ama85/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260518-pod-ama85&utm_content=260518-pod-ama85-podfeed">AMA #85 show notes page</a>. If you are not a subscriber, you can learn more about the subscriber benefits <a href= "https://peterattiamd.com/subscribe/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260518-pod-ama85&utm_content=260518-pod-ama85-podfeed">here</a>.</p> <p><strong>We discuss:</strong></p> <ul type="disc"> <li>How to properly define health problems before considering medications or supplements [1:45];</li> <li>How the intended purpose of an intervention should determine evidence standards and risk tolerance [5:00];</li> <li>Understanding the hierarchy of evidence for medications and supplements and avoiding the mistake of treating weak evidence as clinical proof [9:00];</li> <li>Why mechanistic explanations can be misleading when evaluating longevity interventions [13:15];</li> <li>How baseline risk—and the distinction between relative and absolute risk reduction—changes the real-world benefit of medications and supplements [18:15];</li> <li>Thinking beyond side effects: the many forms of downside associated with medications and supplements [22:45];</li> <li>Why medications and supplements require different standards of trust and evidence [26:00];</li> <li>How to structure meaningful self-experiments with medications and supplements to determine if it's they're working [30:30];</li> <li>How to monitor the effects of medications and supplements without fooling yourself [32:30];</li> <li>How to periodically reevaluate and potentially discontinue medications and supplements [35:15];</li> <li>The biggest risks and failure modes of over-the-counter supplements: efficacy, poor quality control, contamination, interactions, toxicity, and marketing-driven overuse [38:30];</li> <li>Why the US supplement regulatory system creates unreliable products [41:45];</li> <li>A practical framework for evaluating medications and supplements [46:30];</li> <li>Over-the-counter supplements with the best balance of evidence and low downside risk [48:00]; and</li> <li>More.</li> </ul> <p>Connect With Peter on <a href= "https://twitter.com/PeterAttiaMD">Twitter</a>, <a href= "https://www.instagram.com/peterattiamd/">Instagram</a>, <a href="https://www.facebook.com/peterattiamd/">Facebook</a> and <a href="https://www.youtube.com/channel/UC8kGsMa0LygSX9nkBcBH1Sg">YouTube</a></p>

<p><a href= "https://peterattiamd.com/genetictesting/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260518-pod-genetictesting&utm_content=260518-pod-genetictesting-podfeed"> View the Show Notes Page for This Episode</a></p> <p><a href= "https://peterattiamd.com/subscribe/?utm_source=podcast-feed&genetictesting=referral&utm_campaign=260518-pod-genetictesting&utm_content=260518-pod-genetictesting-podfeed"> Become a Member to Receive Exclusive Content</a></p> <p><a href= "https://peterattiamd.com/newsletter/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260518-pod-genetictesting&utm_content=260518-pod-genetictesting-podfeed"> Sign Up to Receive Peter's Weekly Newsletter</a></p> <p>In this episode, Peter explores the complex and often misunderstood world of genetic testing, building a practical framework for understanding what these tests can and cannot actually tell us about health and disease. He explains why some genetic findings can be genuinely life-changing while many others offer information that is far more probabilistic than deterministic, and why directly measuring the phenotype is often more valuable than inferring risk from DNA alone. Peter examines where genetics can provide meaningful insight across the major disease categories and where its predictive power is far more limited than many people assume. He also discusses how to think critically about different types of genetic tests, how to interpret results in the proper context, and how to avoid the common trap of accumulating more genetic information without gaining greater clarity or actionable insight.</p> <p><strong>We discuss:</strong></p> <ul type="disc"> <li>Genetic testing: understanding what it can reveal, where it falls short, and how to think about its clinical value [1:45];</li> <li>The Human Genome Project: why decoding DNA did not immediately unlock the mysteries of disease [4:15];</li> <li>The limitations of genetic testing: probabilistic risk, interpretive uncertainty, and the importance of phenotype [9:30];</li> <li>Questions to ask when considering genetic testing [15:45];</li> <li>Genetic testing in cardiovascular and metabolic disease: when genotype adds value beyond phenotype [17:00];</li> <li>Genetic testing for inherited cardiac conditions: identifying hidden risk beyond routine screening [21:45];</li> <li>Genetic testing for cancer risk: inherited syndromes, clinical utility, and the limits of consumer testing [24:00];</li> <li>Genetic testing for neurodegenerative disease: risk prediction, planning, and the challenge of limited actionability [28:45];</li> <li>Functional medicine genetic testing: the gap between biological plausibility and clinical evidence, and the supplement protocols that aren't supported by evidence [32:45];</li> <li>Pharmacogenetics: using genetic testing to guide medication selection and safety [38:45];</li> <li>A framework for evaluating genetic tests according to effect size and clinical actionability [41:45];</li> <li>The major types of genetic tests, and how each should be matched to the clinical question being asked [43:30];</li> <li>Interpreting genetic test results: choosing the right testing laboratory and understanding what the findings actually mean [49:45];</li> <li>Framework summary: why genetic testing is most valuable when it is guided by a clear question, matched with the appropriate test, and capable of meaningfully influencing decisions [56:45]; and</li> <li>More.</li> </ul> <p>Connect With Peter on <a href= "https://twitter.com/PeterAttiaMD">Twitter</a>, <a href= "https://www.instagram.com/peterattiamd/">Instagram</a>, <a href="https://www.facebook.com/peterattiamd/">Facebook</a> and <a href="https://www.youtube.com/channel/UC8kGsMa0LygSX9nkBcBH1Sg">YouTube</a></p>

<p><a href= "https://peterattiamd.com/colorectalcancerscreening/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260511-pod-colorectalcancerscreening&utm_content=260511-pod-colorectalcancerscreening-podfeed"> View the Show Notes Page for This Episode</a></p> <p><a href= "https://peterattiamd.com/subscribe/?utm_source=podcast-feed&colorectalcancerscreening%20=referral&utm_campaign=260511-pod-colorectalcancerscreening&utm_content=260511-pod-colorectalcancerscreening-podfeed"> Become a Member to Receive Exclusive Content</a></p> <p><a href= "https://peterattiamd.com/newsletter/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260511-pod-colorectalcancerscreening&utm_content=260511-pod-colorectalcancerscreening-podfeed"> Sign Up to Receive Peter's Weekly Newsletter</a></p> <p>In this episode, Peter takes a deep dive into colorectal cancer (CRC) screening, explaining why it is one of the most preventable cancers and why getting screening right can have life-saving implications. He walks through how colorectal cancer develops and why it is uniquely well-suited to early detection and prevention, with a particular emphasis on the dual role of colonoscopy as both a diagnostic and therapeutic tool. Peter also examines the concerning rise in early-onset CRC among younger adults, highlighting why awareness and timely screening matter more than ever. The episode provides a practical guide to preparing for and evaluating the quality of a colonoscopy, including how to think about appropriate screening intervals and the real risks and tradeoffs involved. Finally, Peter explores the expanding landscape of non-invasive screening options, offering clear insight into what these alternatives can and cannot do so listeners can make informed decisions about their care at any age.</p> <p><strong>We discuss:</strong></p> <ul type="disc"> <li>CRC statistics and goals for this episode [1:00];</li> <li>Colorectal cancer development: polyp progression, risk types, and the window for prevention [4:00];</li> <li>Why colorectal cancer is uniquely screenable: direct visualization and the dual role of colonoscopy [6:30];</li> <li>Colonoscopy effectiveness: prevention through polyp removal and interpreting the NordICC trial data [8:15];</li> <li>Rising colorectal cancer in younger adults: trends, possible causes, and the case for earlier screening [12:15];</li> <li>Colonoscopy preparation: why bowel prep matters and how newer options improve the experience [16:45];</li> <li>Colonoscopy quality, polyp miss rates, and personalized screening intervals [20:00];</li> <li>Colonoscopy risks versus colorectal cancer risk: understanding the true risk-benefit tradeoff [29:30];</li> <li>Non-invasive screening options for CRC: benefits, limitations, and their role alongside colonoscopy [37:00];</li> <li>Colorectal cancer prevention principles: why screening matters and the role of colonoscopy [39:30]; and</li> <li>More.</li> </ul> <p>Connect With Peter on <a href= "https://twitter.com/PeterAttiaMD">Twitter</a>, <a href= "https://www.instagram.com/peterattiamd/">Instagram</a>, <a href="https://www.facebook.com/peterattiamd/">Facebook</a> and <a href="https://www.youtube.com/channel/UC8kGsMa0LygSX9nkBcBH1Sg">YouTube</a></p>

<p><a href= "https://peterattiamd.com/ama84/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260504-pod-ama84&utm_content=260504-pod-ama84-podfeed"> View the Show Notes Page for This Episode</a></p> <p><a href= "https://peterattiamd.com/subscribe/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260504-pod-ama84&utm_content=260504-pod-ama84-podfeed"> Become a Member to Receive Exclusive Content</a></p> <p><a href= "https://peterattiamd.com/newsletter/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260504-pod-ama84&utm_content=260504-pod-ama84-podfeed"> Sign Up to Receive Peter's Weekly Newsletter</a></p> <p>In this "Ask Me Anything" (AMA) episode, Peter answers listener questions across a wide range of topics, focusing on how to think through real-world trade-offs and apply scientific evidence in practice. He explores how to build and interpret a meaningful family health history, how individual risk tolerance influences decisions around testing and treatment, and why heart disease remains poorly prevented despite available tools. He also examines whether it's possible to carry excess body fat while remaining metabolically healthy, outlines the minimum effective dose for strength training for those with limited time, and discusses the habits and interventions most likely to reduce dementia risk. Additional topics include what evidence would need to emerge for him to reconsider his current stance on NAD-boosting supplements, and when hydration and electrolyte strategies are truly beneficial versus unnecessary.</p> <p>If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your <a href= "https://peterattiamd.com/members/private-podcast-feed/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260504-pod-ama83&utm_content=260504-pod-ama84-podfeed">private RSS feed </a>or our website at the <a href= "http://peterattiamd.com/ama84/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260504-pod-ama84&utm_content=260504-pod-ama84-podfeed">AMA #84 show notes page</a>. If you are not a subscriber, you can learn more about the subscriber benefits <a href= "https://peterattiamd.com/subscribe/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260504-pod-ama84&utm_content=260504-pod-ama84-podfeed">here</a>.</p> <p><strong>We discuss:</strong></p> <ul type="disc"> <li>Topics overview [1:15];</li> <li>Using family history to assess disease risk: why it matters more than genetic testing and how to analyze it effectively [2:30];</li> <li>Peter's views that differ from conventional medicine: approaches to cardiovascular risk, cancer screening, nutrition, and more [10:30];</li> <li>Risk tolerance in health decisions: weighing action versus inaction and avoiding low-benefit, high-risk interventions [16:00];</li> <li>Why cardiovascular disease persists: delayed treatment, insufficient thresholds, and missed opportunities for early intervention [22:00];</li> <li>Whether someone can be overweight yet metabolically healthy, and how fat distribution influences metabolic risk [26:45];</li> <li>Strength training with limited time: how to maximize results with intensity and efficiency [30:00];</li> <li>Designing a sustainable exercise routine: balancing volume, recovery, and enjoyment over time [34:45];</li> <li>Reducing dementia risk: prioritizing exercise, sleep, and cardiometabolic health based on individual gaps [38:00];</li> <li>Peter's current skepticism toward NAD-related supplements and what evidence would be needed to change his view [40:45];</li> <li>Hydration and electrolytes: factors that impact needs and when supplementation might be necessary [43:30]; and</li> <li>More.</li> </ul> <p>Connect With Peter on <a href= "https://twitter.com/PeterAttiaMD">Twitter</a>, <a href= "https://www.instagram.com/peterattiamd/">Instagram</a>, <a href="https://www.facebook.com/peterattiamd/">Facebook</a> and <a href="https://www.youtube.com/channel/UC8kGsMa0LygSX9nkBcBH1Sg">YouTube</a></p>

<p><a href= "https://peterattiamd.com/thinkingscientifically/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260427-pod-thinkingscientifically&utm_content=260427-pod-thinkingscientifically-podfeed"> View the Show Notes Page for This Episode</a></p> <p><a href= "https://peterattiamd.com/subscribe/?utm_source=podcast-feed&thinkingscientifically%20=referral&utm_campaign=260427-pod-thinkingscientifically&utm_content=260427-pod-thinkingscientifically-podfeed"> Become a Member to Receive Exclusive Content</a></p> <p><a href= "https://peterattiamd.com/newsletter/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260427-pod-thinkingscientifically&utm_content=260427-pod-thinkingscientifically-podfeed"> Sign Up to Receive Peter's Weekly Newsletter</a></p> <p>In this episode, Peter explores one of the most foundational topics underlying nearly everything discussed on the podcast: how to think scientifically. Framed as an introspective deep dive, he examines why scientific thinking is inherently difficult for humans, the cognitive biases and tendencies that make it challenging to separate belief from evidence, and why these challenges are even more consequential in today's environment saturated with misinformation. He also offers a framework for improving our ability to evaluate claims, question assumptions, and identify a personal panel of experts, providing listeners with practical tools to become more disciplined and effective thinkers.</p> <p><strong>We discuss:</strong></p> <ul type="disc"> <li>Topics to be covered and goals for this episode [2:00];</li> <li>Scientific thinking: hypotheses, uncertainty, and the process of ruling out explanations [3:45];</li> <li>How scientific knowledge differs from mathematical proof: useful approximations, evolving evidence, and acting under uncertainty [8:00];</li> <li>Why scientific thinking is difficult: evolution, social instincts, and the need for deliberate practice [13:30];</li> <li>Systems and tools designed to correct human bias [18:15];</li> <li>How to think scientifically pt. 1: Notice when you're feeling certain [20:30];</li> <li>How to think scientifically pt. 2: Judge the process, not just the conclusion [23:00];</li> <li>How to think scientifically pt. 3: Notice when identity is shaping your beliefs [28:15];</li> <li>How to think scientifically pt. 4: Don't confuse criticism with understanding [33:45];</li> <li>How to think scientifically pt. 5: Outsource your thinking carefully [36:15];</li> <li>Evaluating who to trust: incentives, consensus, and red flags in scientific credibility [45:15];</li> <li>Science as a self-correcting system: why updating with evidence is a strength, not a weakness [49:00];</li> <li>The key principles of scientific thinking, and a practical framework for evaluating claims and improving judgment [50:45]; and</li> <li>More.</li> </ul> <p>Connect With Peter on <a href= "https://twitter.com/PeterAttiaMD">Twitter</a>, <a href= "https://www.instagram.com/peterattiamd/">Instagram</a>, <a href="https://www.facebook.com/peterattiamd/">Facebook</a> and <a href="https://www.youtube.com/channel/UC8kGsMa0LygSX9nkBcBH1Sg">YouTube</a></p>

<p><a href= "https://peterattiamd.com/prostatecancerscreening/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260420-pod-prostatecancerscreening&utm_content=260420-pod-prostatecancerscreening-podfeed"> View the Show Notes Page for This Episode</a></p> <p><a href= "https://peterattiamd.com/subscribe/?utm_source=podcast-feed&prostatecancerscreening%20=referral&utm_campaign=260420-pod-prostatecancerscreening&utm_content=260420-pod-prostatecancerscreening-podfeed"> Become a Member to Receive Exclusive Content</a></p> <p><a href= "https://peterattiamd.com/newsletter/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260420-pod-prostatecancerscreening&utm_content=260420-pod-prostatecancerscreening-podfeed"> Sign Up to Receive Peter's Weekly Newsletter</a></p> <p>In this episode, Peter takes a deep dive into prostate cancer screening, explaining why advanced and metastatic diagnoses continue to rise despite the availability of screening tools, and what can be done to reverse this trend. He breaks down what PSA actually measures and why it is far more informative when tracked over time rather than interpreted as a single value, and he explores how tools like MRI, PSA density, PSA velocity, and improved biopsy techniques can both reduce unnecessary procedures and improve the detection of aggressive cancers. Peter also discusses the role of active surveillance in avoiding overtreatment for low-risk cases, examines the flawed evidence that has historically been used to argue against PSA screening, and highlights how medications like finasteride can suppress PSA levels and potentially mask warning signs if not properly accounted for. Ultimately, he makes a compelling case for the importance of regular PSA testing as a key strategy in the effort to eliminate prostate cancer mortality.</p> <p><strong>We discuss:</strong></p> <ul type="disc"> <li>The failure of current prostate cancer screening guidelines, and the rise in advanced disease despite available tools [2:30];</li> <li>PSA screening fundamentals: benefits, harms, and the guideline shift driven by overdiagnosis concerns [5:30];</li> <li>The impact of reduced PSA screening: rising rates of late-stage prostate cancer and worsening population-level outcomes [12:00];</li> <li>How modern screening practices use PSA trends, MRI, and new imaging advances to improve accuracy and reduce unnecessary procedures [15:00];</li> <li>Advances in prostate biopsy: transperineal approach improves safety and cancer detection [23:00];</li> <li>Reducing overtreatment: Gleason scoring and active surveillance in modern prostate cancer care [25:30];</li> <li>Reevaluating PSA screening guidelines: how flaws in the PLCO trial undermine the evidence used to argue against PSA screening [29:45];</li> <li>Prostate cancer screening today: improved tools, flawed guidelines, and preventable mortality [33:45];</li> <li>How finasteride and similar drugs suppress PSA levels and can lead to missed or delayed prostate cancer diagnoses if not properly accounted for [38:00];</li> <li>The optimistic future of prostate cancer: modern screening advances and the potential to reduce mortality [43:15]; and</li> <li>More.</li> </ul> <p>Connect With Peter on <a href= "https://twitter.com/PeterAttiaMD">Twitter</a>, <a href= "https://www.instagram.com/peterattiamd/">Instagram</a>, <a href="https://www.facebook.com/peterattiamd/">Facebook</a> and <a href="https://www.youtube.com/channel/UC8kGsMa0LygSX9nkBcBH1Sg">YouTube</a></p>

<p><a href= "https://peterattiamd.com/ama83/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260413-pod-ama83&utm_content=260413-pod-ama83-podfeed"> View the Show Notes Page for This Episode</a></p> <p><a href= "https://peterattiamd.com/subscribe/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260413-pod-ama83&utm_content=260413-pod-ama83-podfeed"> Become a Member to Receive Exclusive Content</a></p> <p><a href= "https://peterattiamd.com/newsletter/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260413-pod-ama83&utm_content=260413-pod-ama83-podfeed"> Sign Up to Receive Peter's Weekly Newsletter</a></p> <p>In this "Ask Me Anything" (AMA) episode, Peter explores the topic of gray-market peptides, one of the most requested and most confusing topics he's covered on The Drive. Peptides sit at the intersection of biological plausibility, clinical promise, and aggressive commercialization, and are often marketed as cutting-edge therapies for everything from muscle repair and longevity to cosmetic enhancement. Rather than promoting or dismissing peptides wholesale, Peter lays out a clear, repeatable framework for evaluating any peptide or drug—covering mechanism, intended effects, safety, dosing, and alternatives. He distinguishes FDA-approved peptide therapeutics from the loosely regulated "peptides" common in biohacking culture; examines the strengths and limitations of animal and human evidence; unpacks manufacturing, gray-market sales, "research use only" labeling, and third-party testing; addresses oral peptides and absorption challenges; and explains how patents and incentives shape which compounds advance through clinical pipelines. The discussion concludes with a sober look at what would need to change for peptides to become broadly usable therapies, where legitimate peptide therapeutics may expand next, and which areas of medicine stand to benefit most right now.</p> <p>If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your <a href= "https://peterattiamd.com/members/private-podcast-feed/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260413-pod-ama83&utm_content=260413-pod-ama83-podfeed">private RSS feed </a>or our website at the <a href= "http://peterattiamd.com/ama83/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260413-pod-ama83&utm_content=260413-pod-ama83-podfeed">AMA #83 show notes page</a>. If you are not a subscriber, you can learn more about the subscriber benefits <a href= "https://peterattiamd.com/subscribe/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260413-pod-ama83&utm_content=260413-pod-ama83-podfeed">here</a>.</p> <p><strong>We discuss:</strong></p> <ul type="disc"> <li>Setting the framework for evaluating peptides, and explaining the goal of this discussion [3:15];</li> <li>What peptides are: basic definitions, biological roles, and therapeutic foundations [5:30];</li> <li>A framework for evaluating peptides: mechanism, evidence, safety, and regulatory context [10:00];</li> <li>Peptide case study—SS-31: mechanism of action, approved use in Barth syndrome, and other claimed effects [18:15];</li> <li>Does the mechanistic rationale for SS-31 translate into measurable benefits? [22:15];</li> <li>SS-31 continued: safety considerations, gray market risks, the balance of risk versus reward, and why it belongs in bucket #3 [26:00];</li> <li>Peptide case study—melanotan-II: claimed effects, mechanism of action, safety, and side effects [30:45];</li> <li>Melanotan-II continued: weighing the potential risks versus benefits and why it belongs in bucket #2 [36:30];</li> <li>Peptide case study—CJC-1295: growth hormone–stimulating mechanism, claimed effects, and limited human data [40:15];</li> <li>CJC-1295 continued: dosing uncertainty, risk-reward analysis, lack of long-term safety data, limited approved options, and why it belongs in bucket #2 [49:30];</li> <li>Peptide case study—BPC 157: uncertain origins, broad claims, and weak mechanistic evidence [57:45];</li> <li>BPC 157 continued: review of human evidence, lack of replication of animal data, safety considerations, risk-reward analysis, and why it belongs in bucket #1 [1:03:15];</li> <li>Other popular "gray market" peptides and why they mostly fail when under scrutiny [1:11:15];</li> <li>How the evidence on peptides compares to rapamycin, and why the lack of data is the biggest concern [1:20:00];</li> <li>Understanding peptide regulation: FDA approval, supplement oversight, and the risks of gray-market compounds [1:23:00];</li> <li>Inside the gray market: how peptides are sold, regulated, and why testing cannot guarantee safety [1:26:45];</li> <li>Limitations of oral peptides, and examples of peptides in bucket #4 [1:31:45];</li> <li>The future of peptides: real therapeutic potential versus hype in the wellness market [1:35:00]; and</li> <li>More.</li> </ul> <p>Connect With Peter on <a href= "https://twitter.com/PeterAttiaMD">Twitter</a>, <a href= "https://www.instagram.com/peterattiamd/">Instagram</a>, <a href="https://www.facebook.com/peterattiamd/">Facebook</a> and <a href="https://www.youtube.com/channel/UC8kGsMa0LygSX9nkBcBH1Sg">YouTube</a></p>

<p><a href= "https://peterattiamd.com/agingclocks/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260406-pod-agingclocks&utm_content=260406-pod-agingclocks-podfeed"> View the Show Notes Page for This Episode</a></p> <p><a href= "https://peterattiamd.com/subscribe/?utm_source=podcast-feed&agingclocks%20=referral&utm_campaign=260406-pod-agingclocks&utm_content=260406-pod-agingclocks-podfeed"> Become a Member to Receive Exclusive Content</a></p> <p><a href= "https://peterattiamd.com/newsletter/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260406-pod-agingclocks&utm_content=260406-pod-agingclocks-podfeed"> Sign Up to Receive Peter's Weekly Newsletter</a></p> <p>In this episode, Peter takes a deep dive into the science and application of aging clocks, unpacking what they are, the differences between chronological age, biological age, and the pace of aging, and what epigenetic clocks may actually be measuring. He explores key research in the field, including a randomized controlled trial that tested simple lifestyle interventions against several commonly used aging clocks, as well as a study using brain MRI to assess the pace of aging and its relationship to dementia risk and mortality. Throughout the episode, Peter highlights the promises and pitfalls of these tools, ultimately focusing on the field's central question: whether improving an aging clock score truly translates into meaningful clinical outcomes.</p> <p><strong>We discuss:</strong></p> <ul type="disc"> <li>Why aging clocks are being used as proxies for long-term health outcomes and the uncertainty surrounding their clinical value [2:00];</li> <li>How aging clocks use DNA methylation to predict age and how they compare to traditional mortality prediction models [5:00];</li> <li>The shift from aging clocks that predict chronological age to newer models that aim to measure biological age, lifespan differences, and the pace of aging [11:45];</li> <li>The limitations of second-generation aging clocks: biological and measurement noise affecting reliability and interpretation [14:45];</li> <li>Why aging clocks are exciting tools—compression, speed, and individual feedback [17:15];</li> <li>The DO-HEALTH randomized trial: the study design and how different aging clocks were used to measure biological age and the pace of aging [22:00];</li> <li>The DO-HEALTH study results: findings, takeaways, and open questions [27:45];</li> <li>The promise and limitations of aging clocks in measuring meaningful biological aging and predicting health outcomes [33:00];</li> <li>Why aging clocks are not yet reliable as consumer tools and why traditional health metrics still matter most [37:00]; and</li> <li>More.</li> </ul> <p>Connect With Peter on <a href= "https://twitter.com/PeterAttiaMD">Twitter</a>, <a href= "https://www.instagram.com/peterattiamd/">Instagram</a>, <a href="https://www.facebook.com/peterattiamd/">Facebook</a> and <a href="https://www.youtube.com/channel/UC8kGsMa0LygSX9nkBcBH1Sg">YouTube</a></p>

<p><a href= "https://peterattiamd.com/ama82/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260323-pod-ama82&utm_content=260323-pod-ama82-podfeed"> View the Show Notes Page for This Episode</a></p> <p><a href= "https://peterattiamd.com/subscribe/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260323-pod-ama82&utm_content=260323-pod-ama82-podfeed"> Become a Member to Receive Exclusive Content</a></p> <p><a href= "https://peterattiamd.com/newsletter/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260323-pod-ama82&utm_content=260323-pod-ama82-podfeed"> Sign Up to Receive Peter's Weekly Newsletter</a></p> <p>In this "Ask Me Anything" (AMA) episode, Peter answers listener questions across a wide range of topics, focusing on practical decision-making and real-world application. He explores how health priorities and strategies should evolve across different decades of life, which chronic diseases are most challenging to manage and how to think about risk hierarchies, and which emerging interventions—beyond exercise—show the most promise for dementia prevention. Peter also breaks down the utility of wearables and explains how to use and interpret DEXA scans effectively. He discusses the challenges of behavior change and how to make healthy habits stick, along with training strategies for balance, stability, and injury resilience, drawing lessons from his own setbacks. Additional topics include high-protein diets and mTOR, how to weigh mechanisms versus outcomes, how to evaluate diet sodas and non-nutritive sweeteners in context, and a range of listener questions covering health fads, emotional health, and sleep routines.</p> <p>If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your <a href= "https://peterattiamd.com/members/private-podcast-feed/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260323-pod-ama82&utm_content=260323-pod-ama82-podfeed">private RSS feed </a>or our website at the <a href= "http://peterattiamd.com/ama82/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260323-pod-ama82&utm_content=260323-pod-ama82-podfeed">AMA #82 show notes page</a>. If you are not a subscriber, you can learn more about the subscriber benefits <a href= "https://peterattiamd.com/subscribe/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260323-pod-ama82&utm_content=260323-pod-ama82-podfeed">here</a>.</p> <p><strong>We discuss:</strong></p> <ul type="disc"> <li>Overview of episode topics, emphasizing the goal of providing actionable, real-world health guidance  [1:30];</li> <li>How health priorities and training strategies should evolve from early adulthood through older age [2:45];</li> <li>Comparing the four major chronic diseases: which are most preventable, most uncertain, and most concerning [8:00];</li> <li>Emerging strategies for dementia prevention: biomarkers, early detection, and new pharmacologic approaches [15:00];</li> <li>How to use wearable data effectively: when it's helpful, when it's not, and how to avoid over-reliance [19:00];</li> <li>DEXA scans: timing, interpretation, and limitations in body composition and bone density tracking [23:00];</li> <li>Best practices for building sustainable health habits [30:15];</li> <li>How to train your balance and stability [33:30];</li> <li>How to recover from injuries and use setbacks to build strength and resilience [36:15];</li> <li>High protein intake and the impact on mTOR: evaluating mechanisms versus real-world evidence on longevity [38:30];</li> <li>Diet soda and artificial sweeteners: evaluating risks, benefits, and the importance of context [47:00];</li> <li>How to balance enjoying life today with making choices that support long-term health and longevity [51:45]; and</li> <li>More.</li> </ul> <p>Connect With Peter on <a href= "https://twitter.com/PeterAttiaMD">Twitter</a>, <a href= "https://www.instagram.com/peterattiamd/">Instagram</a>, <a href="https://www.facebook.com/peterattiamd/">Facebook</a> and <a href="https://www.youtube.com/channel/UC8kGsMa0LygSX9nkBcBH1Sg">YouTube</a></p>

<p><a href= "https://peterattiamd.com/obicetrapib/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260316-pod-obicetrapib&utm_content=260316-pod-obicetrapib-podfeed"> View the Show Notes Page for This Episode</a></p> <p><a href= "https://peterattiamd.com/subscribe/?utm_source=podcast-feed&%20obicetrapib%20=referral&utm_campaign=260316-pod-obicetrapib&utm_content=260316-pod-obicetrapib-podfeed"> Become a Member to Receive Exclusive Content</a></p> <p><a href= "https://peterattiamd.com/newsletter/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260316-pod-obicetrapib&utm_content=260316-pod-obicetrapib-podfeed"> Sign Up to Receive Peter's Weekly Newsletter</a></p> <p>In this special episode, Peter takes a deep dive into obicetrapib, an investigational drug that has captured his attention and renewed interest in an entire class of therapies known as CETP inhibitors. He explains what obicetrapib is and how it works, revisits the history of CETP inhibitors and why earlier versions of these drugs failed—sometimes dramatically—and breaks down the key clinical trials designed to evaluate their impact on cardiovascular risk. Peter examines how obicetrapib influences major lipid biomarkers, including LDL cholesterol and lipoprotein(a) [Lp(a)], and discusses emerging evidence from a study that explored the drug's effects on Alzheimer's-related blood biomarkers. He also highlights intriguing findings in individuals carrying the APOE4 allele and reflects on what these early results may mean for both cardiovascular disease prevention and potential implications for Alzheimer's risk, as well as how he is thinking about this therapy in the context of caring for his own patients.</p> <p><strong>We discuss:</strong></p> <ul type="disc"> <li>Introducing obicetrapib: CETP inhibitor history, lipid biology, and early Alzheimer's biomarker signals in APOE4 carriers [2:15];</li> <li>CETP biology explained: lipoproteins, reverse cholesterol transport, and how CETP inhibition alters HDL and LDL particles [5:15];</li> <li>The early CETP inhibitor story: why raising HDL cholesterol alone failed to deliver cardiovascular protection [13:45];</li> <li>The rise and fall of early CETP inhibitors: torcetrapib, dalcetrapib, evacetrapib, and anacetrapib [18:30];</li> <li>Why obicetrapib may succeed where earlier CETP inhibitors failed [23:30];</li> <li>The BROADWAY trial: obicetrapib's effects on LDL, ApoB, Lp(a), and residual cardiovascular risk [26:00];</li> <li>Brain lipid metabolism and APOE4: how CETP inhibition may influence cholesterol transport in Alzheimer's disease [30:45];</li> <li>Findings from the substudy of the BROADWAY trial which looked at changes in biomarkers of Alzheimer's disease [40:00];</li> <li>Interpreting the BROADWAY Alzheimer's biomarker results: limitations, cautious optimism, and the need for a dedicated prevention trial [46:45];</li> <li>Why Peter is optimistic about obicetrapib: cardiovascular benefits, Lp(a) reduction, and the path toward approval [50:00]; and</li> <li>More.</li> </ul> <p>Connect With Peter on <a href= "https://twitter.com/PeterAttiaMD">Twitter</a>, <a href= "https://www.instagram.com/peterattiamd/">Instagram</a>, <a href="https://www.facebook.com/peterattiamd/">Facebook</a> and <a href="https://www.youtube.com/channel/UC8kGsMa0LygSX9nkBcBH1Sg">YouTube</a></p>

<p><a href= "https://peterattiamd.com/lisamosconi/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260119-pod-lisamosconi&utm_content=260126-pod-lisamosconi-podfeed"> View the Show Notes Page for This Episode</a></p> <p><a href= "https://peterattiamd.com/subscribe/?utm_source=podcast-feed&lisamosconi%20=referral&utm_campaign=260126-pod-lisamosconi&utm_content=260126-pod-lisamosconi-podfeed"> Become a Member to Receive Exclusive Content</a></p> <p><a href= "https://peterattiamd.com/newsletter/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260126-pod-lisamosconi&utm_content=260126-pod-lisamosconi-podfeed"> Sign Up to Receive Peter's Weekly Newsletter</a></p> <p>Lisa Mosconi is a world-renowned neuroscientist and the director of the Women's Brain Initiative at Weill Cornell Medicine, where she studies how sex differences and hormonal transitions influence brain aging and Alzheimer's disease risk. In this episode, Lisa explores why Alzheimer's disease disproportionately affects women and why longer lifespan alone does not explain their nearly twofold risk compared to men. She explains why Alzheimer's disease may be best understood as a midlife disease for women, beginning decades before symptoms appear, and how menopause represents a fundamental brain event that reshapes brain energy use, structure, and immune signaling. The conversation also examines what advanced brain imaging reveals about preclinical Alzheimer's disease, estrogen receptors in the brain, and why genetic risks such as APOE4 appear to affect women differently from men. Finally, Lisa discusses the nuanced evidence around menopause hormone therapy, the legacy of the WHI, her new CARE Initiative to cut women's Alzheimer's risk in half by 2050, and practical, evidence-based strategies to support brain health through midlife—including lifestyle, sleep, metabolism, mood, and emerging therapies such as GLP-1 agonists and SERMs (selective estrogen receptor modulators).</p> <p><strong>We discuss:</strong></p> <ul type="disc"> <li>How Lisa's personal family history and scientific background led her to focus on the intersection of women's health, brain aging, and Alzheimer's disease (AD) [2:45];</li> <li>The long preclinical phase of AD and the emotional burden carried by patients before dementia becomes severe [7:15];</li> <li>How AD compares to other common forms of dementia: prevalence, pathology, symptoms, diagnostic challenges, and more [10:45];</li> <li>Why AD disproportionately affects women: how AD is not simply a disease of old age or longevity but a midlife disease in which women develop pathology earlier [16:15];</li> <li>Menopause as a leading explanation for women's increased Alzheimer's risk, and how advanced braining imaging can detect early changes in the brain [26:15];</li> <li>How a new method for imaging estrogen receptors in the brain is changing how we think about the menopause transition [35:45];</li> <li>What estrogen receptor imaging can and cannot tell us about hormone therapy's potential impact on brain health [48:45];</li> <li>Lisa's studies on the relationship between levels of systemic estrogen and density of estrogen receptors in the brain [58:00];</li> <li>Why blood estrogen levels poorly reflect brain estrogen signaling, and how tightly regulated brain hormone dynamics complicate our understanding of menstrual-cycle and lifestyle effects [1:02:15];</li> <li>The CARE Initiative: Lisa's research program looking to slash AD rates in women [1:07:45];</li> <li>The dramatic difference in AD risk between men and women associated with APOE4 [1:10:45];</li> <li>What the evidence suggests about menopausal hormone therapy (MHT) and AD risk, and why timing, formulation, and uterine status appear to matter [1:12:00];</li> <li>How the CARE initiative plans to study MHT and AD risk, within the practical constraints of a three-year research window [1:17:30];</li> <li>How to think about starting hormone therapy during perimenopause: balancing symptom relief, hormonal variability, and individualized care [1:21:00];</li> <li>Investigating selective estrogen receptor modulators (SERMs) as a targeted approach to brain health during and after menopause [1:25:00];</li> <li>Why estrogen became wrongly associated with cancer risk and what the evidence actually shows [1:29:30];</li> <li>Why better biomarkers are central to advancing women's Alzheimer's research [1:38:30];</li> <li>Modifiable risk factors for dementia, the limitations of risk models, and questionable conclusions drawn from observational data [1:44:15];</li> <li>GLP-1 agonists and brain health: exploring potential neuroprotective effects of GLP-1 agonists beyond metabolic benefits [1:49:00];</li> <li>The importance of lifestyle factors in reducing risk of dementia: practical strategies for women to support brain health [1:53:45];</li> <li>Why long-term, consistent lifestyle habits are essential for building cognitive resilience and protecting brain health over decades [2:01:15]; and</li> <li>More.</li> </ul> <p>Connect With Peter on <a href= "https://twitter.com/PeterAttiaMD">Twitter</a>, <a href= "https://www.instagram.com/peterattiamd/">Instagram</a>, <a href="https://www.facebook.com/peterattiamd/">Facebook</a> and <a href="https://www.youtube.com/channel/UC8kGsMa0LygSX9nkBcBH1Sg">YouTube</a></p>

<p><a href= "https://peterattiamd.com/laynenorton4/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260119-pod-laynenorton4&utm_content=260119-pod-laynenorton4-podfeed"> View the Show Notes Page for This Episode</a></p> <p><a href= "https://peterattiamd.com/subscribe/?utm_source=podcast-feed&laynenorton4%20=referral&utm_campaign=260119-pod-laynenorton4&utm_content=260119-pod-laynenorton4-podfeed"> Become a Member to Receive Exclusive Content</a></p> <p><a href= "https://peterattiamd.com/newsletter/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260119-pod-laynenorton4&utm_content=260119-pod-laynenorton4-podfeed"> Sign Up to Receive Peter's Weekly Newsletter</a></p> <p>Layne Norton is a nutrition scientist and accomplished power athlete,who returns to The Drive for a conversation that departs from the show's usual format. In this episode, Layne presents the evidence-based case that seed oils are not uniquely harmful under isocaloric conditions, while Peter steelmans the strongest versions of the opposing argument that seed oils are inherently harmful. They examine how scientific bias and evidence are evaluated, revisit the historical randomized controlled trials that shaped the seed oil controversy, and explore the mechanistic biology underlying LDL oxidation and atherosclerosis. Along the way, Layne unpacks the chemistry and processing of modern seed oils, assesses evolutionary and ancestral nutrition arguments, clarifies the relationship between seed oils, ultra-processed foods, and contemporary dietary patterns, and situates these questions within the larger context of lifestyle factors that drive cardiometabolic health. Layne concludes by offering practical considerations around dietary fats, cooking oils, and real-world food choices.</p> <p><strong>We discuss:</strong></p> <ul type="disc"> <li>The idea behind this episode, biases, and evidence-based thinking [5:15];</li> <li>The four core arguments behind claims that seed oils are harmful [12:30];</li> <li>The Minnesota Coronary Experiment (MCE) [14:30];</li> <li>The differences among saturated, monounsaturated, polyunsaturated, and trans fats, and why those differences matter for cardiovascular disease [18:30];</li> <li>Missing trans fat data as a confounder in the Minnesota Coronary Experiment, other limitations of that study, and the challenge detecting meaningful differences in hard outcomes through nutrition research [24:00];</li> <li>The Sydney Diet Heart Study (SDHS): an attempt to address the "duration problem" by enrolling a much higher-risk population [28:30];</li> <li>Debating whether evidence from randomized trials supports the idea that seed oils are uniquely harmful once major confounders are removed [34:00];</li> <li>The Rose Corn Oil trial: an often-cited study used to argue against polyunsaturated fats [36:30];</li> <li>Three studies where replacing saturated fat with polyunsaturated fat produced different results than earlier trials [41:30];</li> <li>Layne's explanation for why the evidence is pointing towards cardiovascular risk reduction when substituting polyunsaturated fat for saturated fat [47:30];</li> <li>What Mendelian randomization says about the causal role of LDL cholesterol in ASCVD [56:45];</li> <li>The compounding effects of life-long exposure to high LDL cholesterol [1:06:45];</li> <li>Does the linoleic acid (omega-6) content of seed oils cause inflammation? [1:13:45];</li> <li>Does the linoleic acid (omega-6) content of seed oils increase oxidized LDL? [1:19:30];</li> <li>Layne's analogy to explain why lower LDL particle number outweighs higher per-particle oxidation risk when comparing polyunsaturated fats to saturated fats [1:26:15];</li> <li>The role of oxidized LDL in CVD: exploring differences in a diet high in polyunsaturated fat (seed oils) versus high in saturated fat [1:28:00];</li> <li>Examining whether industrial processing and solvent extraction of seed oils—especially residual hexane—could plausibly cause long-term harm [1:34:00];</li> <li>The evolutionary and "ancestral diet" argument against seed oils [1:40:45];</li> <li>Weighing concerns about industrial processing of seed oils against the totality of metabolic and cardiovascular evidence [1:47:30];</li> <li>Practical considerations around dietary fats, cooking oils, and real-world food choices [1:50:00];</li> <li>Comparing the health impact of seed oils with that of caloric intake and activity levels, and how to prioritize interventions [2:00:15];</li> <li>More.</li> </ul> <p>Connect With Peter on <a href= "https://twitter.com/PeterAttiaMD">Twitter</a>, <a href= "https://www.instagram.com/peterattiamd/">Instagram</a>, <a href="https://www.facebook.com/peterattiamd/">Facebook</a> and <a href="https://www.youtube.com/channel/UC8kGsMa0LygSX9nkBcBH1Sg">YouTube</a></p>

<p><a href= "https://peterattiamd.com/ama79/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260112-pod-ama79&utm_content=260112-pod-ama79-podfeed"> View the Show Notes Page for This Episode</a></p> <p><a href= "https://peterattiamd.com/subscribe/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260112-pod-ama79&utm_content=260112-pod-ama79-podfeed"> Become a Member to Receive Exclusive Content</a></p> <p><a href= "https://peterattiamd.com/newsletter/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260112-pod-ama79&utm_content=260112-pod-ama79-podfeed"> Sign Up to Receive Peter's Weekly Newsletter</a></p> <p>In this "Ask Me Anything" (AMA) episode, Peter brings together his most up-to-date thinking on cardiorespiratory fitness into a single, practical guide designed to help listeners structure training for maximal impact on healthspan, lifespan, and long-term independence. He explains why cardiorespiratory fitness is one of the strongest modifiable predictors of longevity, clarifies what zone 2 training actually represents and how it differs from higher-intensity work, and addresses persistent confusion around exercise volume, intensity, and time constraints. The discussion covers how to measure and track progress in zone 2, VO₂ max targets and age-adjusted goals, planning for the marginal decade, and how to balance zone 2 with higher-intensity training across different weekly volumes. Peter also outlines how cardio training should be tailored for beginners, experienced trainees, and older adults, with special considerations for women and guidance on avoiding the most common cardio-training mistakes.</p> <p>If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your <a href= "https://peterattiamd.com/members/private-podcast-feed/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260112-pod-ama79&utm_content=260112-pod-ama79-podfeed">private RSS feed </a>or our website at the <a href= "http://peterattiamd.com/ama79/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260112-pod-ama79&utm_content=260112-pod-ama79-podfeed">AMA #79 show notes page</a>. If you are not a subscriber, you can learn more about the subscriber benefits <a href= "https://peterattiamd.com/subscribe/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260112-pod-ama79&utm_content=260112-pod-ama78-podfeed">here</a>.</p> <p><strong>We discuss:</strong></p> <ul type="disc"> <li>Rational for discussing cardiorespiratory fitness, zone 2, and VO₂ max despite having covered the topic extensively [2:30];</li> <li>Why cardiorespiratory fitness and VO₂ max are powerful and modifiable predictors of all-cause mortality compared with other health metrics [7:30];</li> <li>How age-related declines in VO₂ max constrain healthspan and everyday physical function [12:30];</li> <li>The cardiorespiratory fitness triangle: how different training intensities contribute to building the aerobic base, the aerobic peak, and overall aerobic capacity [14:15];</li> <li>The cellular mechanics of cardiorespiratory fitness: mitochondria, lactate, muscle fiber recruitment, and intensity thresholds [18:45];</li> <li>The debate over whether zone 2 training has unique benefits or whether higher-intensity exercise alone is sufficient [27:15];</li> <li>Balancing intensity and sustainability as training volume increases, and the important role of zone 2 training [32:15];</li> <li>How to identify your zone 2 training intensity [34:45];</li> <li>How to measure and track improvements in zone 2 fitness [40:00];</li> <li>How to accurately measure VO₂ max: lab testing, field tests, and the limits of wearables [45:15];</li> <li>How to set meaningful VO₂ max targets based on age, sex, long-term decline, and desired physical capabilities later in life [51:15];</li> <li>How to structure and execute a zone 2 workout [59:45];</li> <li>How strictly should zone 2 be maintained during a workout? [1:04:00];</li> <li>How to design a VO₂ max training session: interval length, intensity, recovery, and progression strategies [1:07:00];</li> <li>Why heart rate is not a reliable metric for titrating VO₂ max interval intensity [1:12:00];</li> <li>Practical ways to monitor VO₂ max improvements [1:13:30];</li> <li>How to balance zone 2 and VO₂ max training [1:15:30];</li> <li>How to structure training for someone limited to 150 minutes per week of total exercise [1:19:00];</li> <li>How to allocate 150 minutes per week of dedicated cardiorespiratory training between zone 2 and VO₂ max work [1:23:00];</li> <li>How to structure training for someone with substantial available time who wants to maximize cardiorespiratory fitness [1:24:30];</li> <li>Why spreading aerobic training across the week beats compressing volume into one session [1:26:15];</li> <li>How beginners and metabolically unhealthy individuals should start cardiorespiratory training safely [1:28:00];</li> <li>How "training age" determines the intensity and workload needed to continue improving cardiorespiratory fitness [1:31:15];</li> <li>Why zone 2 training still matters for women (including postmenopausal women) [1:32:45];</li> <li>How cardiorespiratory training should adapt with aging [1:35:45];</li> <li>The most common mistakes people make when training cardiorespiratory fitness and how to avoid them [1:37:45];</li> <li>How to break through a VO₂ max plateau [1:40:45];</li> <li>The main takeaways about cardiorespiratory fitness and longevity [1:41:30];</li> <li>Peter's carve out: oral hygiene and Peter's two-toothbrush system [1:43:00]; and</li> <li>More.</li> </ul> <p>Connect With Peter on <a href= "https://twitter.com/PeterAttiaMD">Twitter</a>, <a href= "https://www.instagram.com/peterattiamd/">Instagram</a>, <a href="https://www.facebook.com/peterattiamd/">Facebook</a> and <a href="https://www.youtube.com/channel/UC8kGsMa0LygSX9nkBcBH1Sg">YouTube</a></p>

<p><a href= "https://peterattiamd.com/carolehooven/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=251201-pod-carolehooven&utm_content=251201-pod-antoniobianco-podfeed"> View the Show Notes Page for This Episode</a></p> <p><a href= "https://peterattiamd.com/subscribe/?utm_source=podcast-feed&carolehooven%20=referral&utm_campaign=251201-pod-carolehooven&utm_content=251201-pod-antoniobianco-podfeed"> Become a Member to Receive Exclusive Content</a></p> <p><a href= "https://peterattiamd.com/newsletter/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=251201-pod-carolehooven&utm_content=251201-pod-carolehooven-podfeed"> Sign Up to Receive Peter's Weekly Newsletter</a></p> <p>Carole Hooven is a human evolutionary biologist whose research centers on testosterone, sex differences, and behavior. In this episode, she explores how prenatal testosterone orchestrates male development in the body and brain, how early hormonal surges shape lifelong behavioral tendencies, and what rare natural experiments—such as 5-alpha-reductase deficiency—reveal about the biology of sex differentiation. She discusses distinct male and female aggression styles through an evolutionary lens, how modern environments interact with ancient competitive drives, and the implications of attempting to suppress them. The conversation also covers testosterone across the lifespan, the role of hormone therapy in both men and women, and Carole's own experience after surgical menopause, culminating in a broader discussion of masculinity, cultural narratives, and the consequences of denying biological sex differences.</p> <p><strong>We discuss:</strong></p> <ul type="disc"> <li>How Carole became interested in exploring the biological and evolutionary roots of sex differences and the role of testosterone [2:30];</li> <li>How testosterone and other hormones influence sex differences in aggression and behavior across species [9:45];</li> <li>How chromosomes, the SRY gene, and early hormones direct embryonic sexual differentiation [12:15];</li> <li>A stark contrast of male social bonding compared to females, and evolutionary parallels in chimpanzees [19:30];</li> <li>How hormones like DHT shape sexual differentiation, and how 5⍺-reductase deficiency reveals the distinct roles of these hormones [22:45];</li> <li>How sex chromosomes and prenatal testosterone shape early brain development and explain sex differences in childhood behavior [31:30];</li> <li>How gamete differences shape reproductive strategies, energetic costs, and sex-specific behavior [42:30];</li> <li>How evolutionary biology shapes sex differences in play, aggression, and conflict resolution (and how modern environments and cultural messaging can disrupt those patterns) [49:00];</li> <li>Why males commit disproportionately more violent crime, and how cultural and environmental forces shape aggression [1:01:00];</li> <li>Why females evolved different behavioral strategies: nurturing, risk aversion, and the cultural norms that override biology [1:04:00];</li> <li>Whether male aggression is still necessary in modern society, why the underlying biological drives persist, and how modern society redirects these drives [1:06:30];</li> <li>How testosterone levels naturally shift to support fatherhood and caregiving [1:13:30];</li> <li>How testosterone shapes male mating strategies, and why long-term pair-bonding persists even when reproduction is no longer at stake [1:18:30];</li> <li>The distinct roles of estrogen in male development, mood, libido, and muscle [1:25:00];</li> <li>How evolution, health, lifestyle, and androgen receptor biology shape modern testosterone replacement therapy (TRT) [1:34:15];</li> <li>Carole's experience with hormone replacement therapy (HRT), and the risks associated with TRT in younger men [1:45:15];</li> <li>How Carole rebuilt after controversy: leaving academia and recommitting to scientific honesty [1:51:30,];</li> <li>Carole's next book: examining masculinity, cultural narratives, and the cost of denying biological sex differences [1:57:30]; and</li> <li>More.</li> </ul> <p>Connect With Peter on <a href= "https://twitter.com/PeterAttiaMD">Twitter</a>, <a href= "https://www.instagram.com/peterattiamd/">Instagram</a>, <a href="https://www.facebook.com/peterattiamd/">Facebook</a> and <a href="https://www.youtube.com/channel/UC8kGsMa0LygSX9nkBcBH1Sg">YouTube</a></p>

<p><a href= "https://peterattiamd.com/antoniobianco/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=251117-pod-antoniobianco&utm_content=251117-pod-antoniobianco-podfeed"> View the Show Notes Page for This Episode</a></p> <p><a href= "https://peterattiamd.com/subscribe/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=251117-pod-antoniobianco&utm_content=251117-pod-antoniobianco-podfeed"> Become a Member to Receive Exclusive Content</a></p> <p><a href= "https://peterattiamd.com/newsletter/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=251117-pod-antoniobianco&utm_content=251117-pod-antoniobianco-podfeed"> Sign Up to Receive Peter's Weekly Newsletter</a></p> <p>Antonio Bianco is a world-renowned physician-scientist and expert in thyroid physiology and metabolism. In this episode, Antonio explores the complex biology of thyroid hormone production, conversion, and regulation—highlighting how deiodinase enzymes modulate hormone activity at the tissue level and why that matters for interpreting lab results. He discusses the shortcomings of relying solely on TSH as a marker of thyroid function, the ongoing debate around combination therapy with T3 and T4 versus standard T4 treatment, and how genetics, tissue sensitivity, and individual variability influence thyroid hormone metabolism. The conversation also examines how hypothyroidism affects energy, mood, cognition, and longevity; why some patients remain symptomatic despite "normal" labs; and how future research could reshape treatment paradigms.</p> <p><strong>We discuss:</strong></p> <ul type="disc"> <li>How the thyroid produces, stores, and activates hormones like T4 and T3 to finely regulate thyroid activity [2:45];</li> <li>How fasting alters thyroid hormones to conserve energy [12:45];</li> <li>Action of the deiodinases: how D1, D2, and D3 enzymes control the activation and inactivation of thyroid hormones [19:15];</li> <li>The normal function of thyroid hormone and the roles of the hypothalamus, pituitary gland, and deiodinases in maintaining hormonal balance [23:30];</li> <li>Why understanding thyroid physiology is essential for proper diagnosis and treatment of hypothyroidism [33:45];</li> <li>Testing for thyroid hormones: understanding free vs. total levels, the limitations of current T3 assays, best practices, and more [36:00];</li> <li>Genetic and sex-based variability in thyroid hormone regulation and their limited clinical significance [43:45];</li> <li>Hyperthyroidism: causes, symptoms, diagnosis, and treatment options [46:00];</li> <li>Hypothyroidism: diagnosis and autoimmune causes of hypothyroidism [56:30];</li> <li>More on hypothyroidism: diagnostic biomarkers, antibody patterns, and non-autoimmune presentations [1:05:00];</li> <li>Thyroid hormone replacement therapy [1:15:15];</li> <li>More on thyroid replacement strategies: exploring the evidence gaps, mortality signals, effects on lipids, and more [1:28:00];</li> <li>Hypothyroidism basics: causes, antibody implications (including pregnancy), and how to make the diagnosis before choosing therapy [1:35:15];</li> <li>Thyroid medication: compounded controlled-release T3, brand name versus generic, and what Antonio prescribes to newly diagnosed hypothyroid patients [1:42:45];</li> <li>Redefining treatment success: why normalizing TSH isn't always enough for patients with hypothyroidism [1:54:45];</li> <li>Case studies: analysis of two unusual cases of thyroid disease [1:57:00];</li> <li>Dangers of supplementing with high levels of iodine, and female-specific risk of thyroid disease [2:05:45];</li> <li>Case study of a patient who presents with elevated TSH but no symptoms [2:09:30];</li> <li>How future research could reshape treatment, and Antonio's new book called "Rethinking Hypothyroidism" [2:13:15]; and</li> <li>More.</li> </ul> <p>Connect With Peter on <a href= "https://twitter.com/PeterAttiaMD">Twitter</a>, <a href= "https://www.instagram.com/peterattiamd/">Instagram</a>, <a href="https://www.facebook.com/peterattiamd/">Facebook</a> and <a href="https://www.youtube.com/channel/UC8kGsMa0LygSX9nkBcBH1Sg">YouTube</a></p>

<p><a href= "https://peterattiamd.com/ama77/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=251110-pod-ama76&utm_content=251110-pod-ama77-podfeed"> View the Show Notes Page for This Episode</a></p> <p><a href= "https://peterattiamd.com/subscribe/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=251110-pod-ama77&utm_content=251110-pod-ama77-podfeed"> Become a Member to Receive Exclusive Content</a></p> <p><a href= "https://peterattiamd.com/newsletter/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=251110-pod-ama77&utm_content=251110-pod-ama77-podfeed"> Sign Up to Receive Peter's Weekly Newsletter</a></p> <p>In this "Ask Me Anything" (AMA) episode, Peter breaks down the science of dietary fiber, moving beyond the blanket advice to "eat more fiber" to uncover what it actually does in the body and where its benefits are truly supported by evidence. He explains how different types of fiber—soluble, insoluble, viscous, and fermentable—affect digestion, satiety, weight management, and glycemic control, and compares their impact to other, more potent metabolic tools. Peter also examines how certain fibers influence lipid metabolism and cardiovascular risk, evaluates the strength of evidence for fiber's role in colorectal cancer prevention, and highlights why some individuals may not tolerate specific fibers well. The discussion concludes with practical guidance on moving past generic fiber targets toward a more strategic and personalized approach that maximizes the true benefits of fiber.</p> <p>If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your <a href= "https://peterattiamd.com/members/private-podcast-feed/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=251110-pod-ama76&utm_content=251110-pod-ama77-podfeed">private RSS feed </a>or our website at the <a href= "http://peterattiamd.com/ama77/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=251110-pod-ama77&utm_content=251110-pod-ama77-podfeed">AMA #77 show notes page</a>. If you are not a subscriber, you can learn more about the subscriber benefits <a href= "https://peterattiamd.com/subscribe/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=251110-pod-ama77&utm_content=251119-pod-ama77-podfeed">here</a>.</p> <p><strong>We discuss:</strong></p> <ul type="disc"> <li>Why it's time to re-examine the evidence behind dietary fiber recommendations [2:00];</li> <li>Why it's hard to isolate fiber's true effects on health: the limits of nutritional epidemiology [5:45];</li> <li>Defining dietary fiber: what it is, how it's digested, and why different types have different effects [8:15];</li> <li>Understanding fiber properties: how solubility, viscosity, and fermentability shape its effects in the body [11:15];</li> <li>Resistant starches explained: types, food sources, and how cooking and cooling influence their benefits [16:30];</li> <li>A framework for evaluating each of the major health claims linked to fiber [19:15];</li> <li>How fiber can support weight loss: mechanisms, realistic expectations, and its complementary role to broader dietary strategies [20:30];</li> <li>How fiber modestly improves glycemic control by reducing glucose spikes and insulin demand [26:15];</li> <li>How fiber modestly lowers LDL cholesterol and supports cardiovascular health [34:30];</li> <li>How fiber compares to other available tools and strategies for managing lipids, blood sugar, and weight [42:00];</li> <li>Fiber's role in colon cancer prevention: mechanisms, evidence, and limitations [45:30];</li> <li>Is fiber necessary for colon cancer prevention in otherwise healthy individuals? [53:30];</li> <li>Why some people have adverse reactions to certain types of fiber, and how to manage them [56:00];</li> <li>A general strategy for dietary fiber: combine multiple fiber types through whole foods and supplements [58:45];</li> <li>Why total fiber intake is more important than the ratio of soluble-to-insoluble fiber [1:02:45];</li> <li>The optimal timing and context for consuming fiber to maximize blood sugar control and metabolic benefits [1:05:00];</li> <li>How food processing affects the functional properties of fiber, the differences between supplement forms and natural sources, and why whole foods generally remain the best option [1:06:45];</li> <li>Fiber's potential to interfere with medication absorption [1:09:30];</li> <li>How to safely increase fiber intake: ramp up gradually and stay hydrated [1:12:00];</li> <li>Final takeaway on fiber: modest benefits, strong rationale, low downside [1:13:00];</li> <li>Peter's carve-out: lessons and inspiration from the Acquired podcast [1:14:30]; and</li> <li>More.</li> </ul> <p>Connect With Peter on <a href= "https://twitter.com/PeterAttiaMD">Twitter</a>, <a href= "https://www.instagram.com/peterattiamd/">Instagram</a>, <a href="https://www.facebook.com/peterattiamd/">Facebook</a> and <a href="https://www.youtube.com/channel/UC8kGsMa0LygSX9nkBcBH1Sg">YouTube</a></p>